Amneal Pharmaceuticals (NASDAQ:AMRX) Sees Large Volume Increase – Here’s What Happened

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) saw unusually-strong trading volume on Wednesday . Approximately 2,753,723 shares were traded during mid-day trading, an increase of 81% from the previous session’s volume of 1,522,188 shares.The stock last traded at $13.9050 and had previously closed at $13.83.

Analyst Ratings Changes

Several research analysts have issued reports on AMRX shares. Truist Financial set a $15.00 price target on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Barclays started coverage on Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 target price on the stock. Piper Sandler reiterated an “overweight” rating and issued a $13.00 price target (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research report on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $13.80.

Amneal Pharmaceuticals Stock Performance

The company has a 50-day simple moving average of $12.69 and a 200-day simple moving average of $10.75. The stock has a market cap of $4.40 billion, a P/E ratio of 699.10 and a beta of 1.34.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.The firm had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Nikita Shah sold 131,856 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the completion of the transaction, the executive vice president directly owned 146,403 shares in the company, valued at approximately $1,745,123.76. The trade was a 47.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ted C. Nark sold 50,000 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $11.72, for a total transaction of $586,000.00. Following the completion of the transaction, the director directly owned 291,029 shares in the company, valued at $3,410,859.88. The trade was a 14.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 231,856 shares of company stock valued at $2,743,724 in the last 90 days. 17.45% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Amneal Pharmaceuticals by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock worth $793,000 after acquiring an additional 4,178 shares during the period. Millennium Management LLC grew its stake in shares of Amneal Pharmaceuticals by 32.6% in the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock worth $17,492,000 after purchasing an additional 512,842 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Amneal Pharmaceuticals in the 1st quarter valued at about $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Amneal Pharmaceuticals by 5.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock valued at $2,807,000 after buying an additional 16,536 shares during the period. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of Amneal Pharmaceuticals in the second quarter worth approximately $113,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.